Cancer Research - Europa

Selected (WP2)
and RNAi screen
identifi ed (WP3,6)
signaling pathway
inhibitors
Coordinator
Petri Salven
University of Helsinki
Helsinki, Finland
petri.salven@helsinki.fi
Partners
Peter ten Dijke
Leiden University Medical Center
Leiden, The Netherlands
Luigi Naldini
San Raffaele Telethon
Institute for Gene Therapy
Milan, Italy
Kari Alitalo
Jussi Taipale
University of Helsinki
Helsinki, Finland
WP5: Angionic factors,
Factors recruiting stromal
and BM derived cells
Tumor Host
WP6: Tumor growth factors
Validited host-cell specifi c
regulatory elements (WP4)
Lentiviral targering (WP7,8)
Summary of the science and technology objectives of the project, and the work package structure.
The project aims to develop novel tools and methods to study tumour-host interactions in cancer,
and to apply these techniques to the identifi cation of molecules and processes in normal cells, which
could be targeted by novel anti-cancer therapeutic agents. In addition, we will also develop targeted
lentiviruses that specifi cally express genes in bone marrow-derived cells and/or in endothelial cells,
which would allow in vivo delivery of therapeutic agents into tumours.
Abbreviations: BM, bone marrow; RNAi, RNA interference; WP, work package.
84
Selected (WP2) and RNAi screen
identifi ed (WP3) signalising
pathway inhibitors
Project number
LSHC-CT-2005-518198
EC contribution
€ 2 700 000
Duration
36 months
Starting date
01/11/2005
Instrument
STREP
Project website
research.med.helsinki.
fi /tumorhostgenomics/
default.htm
CANCER RESEARCH PROJECTS FUNDED UNDER THE SIXTH FRAMEWORK PROGRAMME